| A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy (NCT05104775) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-02-09 |
| The Effect of Lavender Oil on Fatigue and Sleep Quality (NCT05808296) | Istanbul Aydın University | 2022-01-01 |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (NCT04588922) | Sellas Life Sciences Group | 2021-05-10 |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (NCT04728893) | Merck Sharp & Dohme LLC | 2021-04-05 |
| A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (NCT04696809) | Janssen Pharmaceutical K.K. | 2021-02-22 |
| Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology (NCT04758442) | Ciusss de L'Est de l'Île de Montréal | 2021-02-01 |
| An Online-platform to Improve Patient-centered Care During the COVID-19 Pandemic: a GIMEMA Surveillance Program in Hematologic Malignancies (NCT04581187) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2020-12-02 |
| RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies (NCT04538599) | He Huang | 2020-09-10 |
| Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease (NCT04112810) | Medical College of Wisconsin | 2020-03-01 |
| Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients (NCT04478916) | Lorenza Scotti | 2019-12-18 |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors (NCT04214093) | AstraZeneca | 2019-12-16 |
| A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies (NCT03557619) | AbbVie | 2019-07-30 |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (NCT03486873) | Merck Sharp & Dohme LLC | 2018-08-21 |
| APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies (NCT03537482) | Ascentage Pharma Group Inc. | 2018-08-07 |
| GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease (NCT03320642) | Incyte Corporation | 2018-02-27 |
| Register of Blood Stem Cell Transplantation (NCT04263857) | Technical University of Munich | 2017-11-01 |
| Therapy for Progressive and/or Refractory Hematologic Malignancies (NCT02223312) | Kiromic BioPharma Inc. | 2017-07-28 |
| Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients (NCT03609840) | University of California, San Francisco | 2017-05-24 |
| Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia (NCT02964325) | Terumo BCTbio | 2017-05-05 |
| Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies (NCT02985554) | University of Chicago | 2017-03-20 |
| A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (NCT03082209) | AbbVie | 2017-03-20 |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies (NCT02743351) | Fate Therapeutics | 2016-12-20 |
| Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (NCT02921685) | Institut Paoli-Calmettes | 2016-11-28 |
| Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors (NCT02301065) | St. Jude Children's Research Hospital | 2016-10-13 |
| Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients (NCT03212560) | Gazi University | 2016-10-01 |
| Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies (NCT02487459) | Bellicum Pharmaceuticals | 2016-07-01 |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant (NCT02118311) | Masonic Cancer Center, University of Minnesota | 2016-06-01 |
| Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation (NCT02786628) | UNC Lineberger Comprehensive Cancer Center | 2016-02-01 |
| A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors (NCT02663518) | Pfizer | 2016-01-28 |
| Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT) (NCT03609814) | University of California, San Francisco | 2016-01-26 |
| Matching Patients With Hematologic Malignancy to Adequate Clinical Trials (NCT02758080) | Seoul National University Hospital | 2016-01-01 |
| A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders (NCT02494258) | Celgene | 2015-10-22 |
| Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device (NCT02600208) | Julie-An M. Talano | 2015-10-01 |
| Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients (NCT03609827) | University of California, San Francisco | 2015-09-01 |
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation (NCT02492737) | Agios Pharmaceuticals, Inc. | 2015-08-07 |
| Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation (NCT02342613) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-05-28 |
| Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies (NCT02343679) | Anne Beaven, MD | 2015-05-01 |
| Safety of Romiplostim (Nplate®) Following UCBT (NCT02046291) | Masonic Cancer Center, University of Minnesota | 2015-04-10 |
| A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies (NCT02386332) | Instituto de Investigacion Sanitaria La Fe | 2015-03-01 |
| Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials (NCT02315599) | National Cancer Institute (NCI) | 2014-12-23 |
| A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies (NCT02354417) | Fate Therapeutics | 2014-12-01 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02129582) | Case Comprehensive Cancer Center | 2014-11-05 |
| Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies (NCT02145403) | University of Michigan Rogel Cancer Center | 2014-10-01 |
| Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation (NCT01788605) | The Catholic University of Korea | 2014-08-01 |
| BGJ398 for Patients With Tumors With FGFR Genetic Alterations (NCT02160041) | Novartis Pharmaceuticals | 2014-07-24 |
| LGX818 for Patients With BRAFV600 Mutated Tumors (NCT01981187) | Pfizer | 2014-01-14 |
| Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy (NCT02139280) | Dartmouth-Hitchcock Medical Center | 2013-12-01 |
| Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation (NCT01882374) | Tarix Pharmaceuticals | 2013-12-01 |
| Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (NCT01882387) | Tarix Pharmaceuticals | 2013-12-01 |
| Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment (NCT01949545) | Amgen | 2013-10-01 |
| Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease (NCT02032446) | A.O. Ospedale Papa Giovanni XXIII | 2013-09-01 |
| Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction (NCT01912222) | Millennium Pharmaceuticals, Inc. | 2013-08-01 |
| An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate (NCT01844869) | Teva Branded Pharmaceutical Products R&D, Inc. | 2013-07-01 |
| Clinical Cohort of Lymphoma Patients in Malawi (NCT02835911) | UNC Lineberger Comprehensive Cancer Center | 2012-11-01 |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation (NCT01810588) | Weill Medical College of Cornell University | 2012-10-16 |
| Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life (NCT01930981) | Fred Hutchinson Cancer Center | 2012-10-01 |
| A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies (NCT02623439) | University of California, San Diego | 2012-09-21 |
| Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation (NCT01749293) | University of Illinois at Chicago | 2012-08-30 |
| The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. (NCT01627314) | Fate Therapeutics | 2012-07-01 |
| Phase I Study of mPEG-R-Crisantaspase Given IV (NCT01551524) | Jazz Pharmaceuticals | 2012-03-01 |
| A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care (NCT01725022) | Duke University | 2012-02-01 |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies (NCT01622556) | University of Virginia | 2012-01-01 |
| Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation (NCT01460420) | European Myeloma Network B.V. | 2011-11-01 |
| Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia (NCT01380756) | Amgen | 2011-10-04 |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) (NCT01351545) | Center for International Blood and Marrow Transplant Research | 2011-10-01 |
| A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors (NCT01375842) | Genentech, Inc. | 2011-06-21 |
| Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen (NCT01328496) | St. Jude Children's Research Hospital | 2011-06-15 |
| Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies (NCT01260545) | Janssen Research & Development, LLC | 2011-04-30 |
| Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps (NCT01350258) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-04-01 |
| AMG 319 Lymphoid Malignancy FIH (NCT01300026) | Amgen | 2011-04-01 |
| Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT01237639) | Ottawa Hospital Research Institute | 2011-03-01 |
| Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies (NCT01351350) | Millennium Pharmaceuticals, Inc. | 2011-02-28 |
| Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. (NCT00890500) | Fate Therapeutics | 2011-01-01 |
| Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (NCT01316549) | University of California, San Francisco | 2011-01-01 |
| Elderly CAncer Patient (NCT02884375) | Assistance Publique - Hôpitaux de Paris | 2010-09-01 |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (NCT01203722) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2010-09-01 |
| Dose Escalation of IPI-493 in Hematologic Malignancies (NCT01193491) | Infinity Pharmaceuticals, Inc. | 2010-06-01 |
| Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation (NCT01217723) | McMaster University | 2010-04-01 |
| A Study Of PF-04449913 In Select Hematologic Malignancies (NCT00953758) | Pfizer | 2010-03-03 |
| Umbilical Cord Transplantation for the Elderly Population (NCT01484470) | Loyola University | 2010-01-01 |
| Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide (NCT01010217) | M.D. Anderson Cancer Center | 2009-11-05 |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer (NCT00881946) | Accenture | 2009-07-01 |
| Cytokine Induced Killer (CIK) Cells In Leukemia Patients (NCT01186809) | A.O. Ospedale Papa Giovanni XXIII | 2009-07-01 |
| Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets (NCT01687231) | Duke University | 2009-04-01 |
| Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant (NCT00810602) | Pavan Reddy, MD | 2009-01-01 |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies (NCT00824135) | St. Jude Children's Research Hospital | 2009-01-01 |
| Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia (NCT00677859) | Healios K.K. | 2008-07-01 |
| Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies (NCT00660920) | Ariad Pharmaceuticals | 2008-06-01 |
| Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) (NCT00750737) | M.D. Anderson Cancer Center | 2008-06-01 |
| Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma (NCT00722488) | Millennium Pharmaceuticals, Inc. | 2008-06-01 |
| Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies (NCT00675831) | Dana-Farber Cancer Institute | 2007-12-01 |
| Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation (NCT01081405) | Fondazione EMN Italy Onlus | 2007-11-01 |
| Adult Double Cord Blood Transplant Study (NCT00514579) | Center for International Blood and Marrow Transplant Research | 2007-08-01 |
| Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies (NCT00521859) | M.D. Anderson Cancer Center | 2007-08-01 |
| Phase II Trial of Pentostatin and Targeted Busulfan (NCT00496340) | H. Lee Moffitt Cancer Center and Research Institute | 2007-07-01 |
| Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan (NCT00843947) | University of California, Davis | 2007-06-01 |
| A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT (NCT00477542) | Indiana University | 2007-05-01 |
| A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders (NCT00596999) | Celgene Corporation | 2007-05-01 |
| A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine (NCT00741234) | S*BIO | 2007-04-01 |
| Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies (NCT00689884) | Dartmouth-Hitchcock Medical Center | 2007-01-01 |